• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,319.55 185.23
( 0.25%)
Global Indices
Nasdaq
46,525.67 -61.07
(-0.13%)
Dow Jones
6,603.69 7.37
(0.11%)
Hang Seng
53,162.49 699.22
(1.33%)
Nikkei 225
10,436.29 71.50
(0.69%)
Forex
USD-INR
93.02 -0.15
(-0.16%)
EUR-INR
107.32 -0.65
(-0.60%)
GBP-INR
123.03 -0.78
(-0.63%)
JPY-INR
0.58 0.00
(-0.67%)

EQUITY - MARKET SCREENER

Pavna Industries Ltd
Industry :  Auto Ancillaries
BSE Code
ISIN Demat
Book Value()
543915
INE07S101038
13.8693256
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
PAVNAIND
39.68
221.43
EPS(TTM)
Face Value()
Div & Yield %
0.4
1
0
 

USFDA completes inspection of Enzene's manufacturing unit at Chakan, Pune
Feb 16,2026
Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13 February, 2026 at the manufacturing facility of Enzene Biosciences (Enzene), a subsidiary of the Company in India located at Chakan, Pune.

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity – a critical validation of Enzene's quality systems and the reliability of regulatory filings.

Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions.